OpenEvidence AI search engine used by nearly two-thirds of US physicians
The ad-supported medical chatbot claims high adoption among US doctors, with projections suggesting significant future revenue from its commercial model.
Key points
- OpenEvidence states nearly two-thirds of approximately one million US physicians use its AI search tool.
- A source indicates the platform is on track to generate between $400 million and $500 million in ad revenue in 2026.
- The widespread use of an advertising-funded medical tool has sparked debate regarding the impact on patient care standards.
OpenEvidence reports that nearly two-thirds of roughly one million physicians in the United States are currently using its artificial intelligence search engine. This adoption figure comes as the company prepares for significant financial growth, with industry sources projecting substantial advertising revenue for the coming year.
According to a report by the Financial Times, a source indicates that OpenEvidence is on track to generate between $400 million and $500 million in advertising revenue in 2026. The platform operates as an ad-powered tool, meaning its business model relies on displaying commercial messages to its large base of medical professional users.
Business Model and Industry Reaction
The founder of the OpenEvidence chatbot confirmed the high usage rates among US doctors, a disclosure that has triggered a broader conversation within the healthcare sector. Critics and observers are debating whether the integration of advertising into a clinical decision-support tool compromises the integrity of patient care. The reliance on ad revenue introduces a potential conflict of interest that professionals are now scrutinizing.
The Financial Times highlighted this specific tension between commercial viability and medical ethics in its coverage. The scale of adoption suggests that many clinicians are accustomed to using AI tools that may contain commercial biases. This situation raises questions about how advertising influences the information presented to doctors during their daily practice routines.
Impact on Medical Professionals
With nearly two-thirds of the estimated one million US physicians using the service, the reach of OpenEvidence is considerable. This widespread adoption implies that a significant portion of clinical decisions may be influenced by an AI system funded by external advertisers. The sheer volume of users amplifies the potential impact of any bias or commercial pressure embedded in the search results.
Medical professionals using the tool are exposed to this ad-supported environment regularly. The debate centers on whether patients benefit from the efficiency of AI search or if they are at risk due to the commercial underpinnings of the technology. The lack of transparency regarding how ads are selected or displayed remains a key concern for those evaluating the tool's safety.
What should you do?
Healthcare organizations should review their current use of third-party AI tools to understand the funding models behind them. Clinicians should remain aware that ad-supported platforms may prioritize certain information over others. Regulatory bodies may need to evaluate whether current guidelines adequately address the commercialization of clinical decision support systems. Patients should ask their providers about the tools used to inform their care plans.
What to do and how to stay safe: OpenEvidence
- Review the terms of service and privacy policies for any AI medical tools to identify advertising or data-sharing practices.
- Verify clinical recommendations from AI tools against established medical guidelines and peer-reviewed literature before application.
- Monitor industry reports and regulatory updates regarding the ethical standards for ad-supported healthcare technologies.
- Discuss with healthcare providers which digital tools are used in your care and how they are funded.
Step-by-step guide: Prompt Injection Warning Signs: How to Spot AI Manipulation
General security guidance from the Threat Times newsroom. It is not confirmed advice from the organisations named in this story.
Frequently asked questions
How many US physicians use OpenEvidence?
OpenEvidence states that nearly two-thirds of approximately one million US physicians use its AI search engine.
What is the projected revenue for OpenEvidence in 2026?
A source cited by the Financial Times says OpenEvidence is on track to generate $400 million to $500 million in ad revenue in 2026.
Why is there debate about OpenEvidence?
The debate arises because the tool is ad-powered, raising concerns about how commercial interests might affect patient care and clinical decisions.
